Evidence map›Paper›PMID 39828766›Full record

ArticleSignal transduction and targeted therapy2025

Isoxazole-based molecules restore NK cell immune surveillance in hepatocarcinogenesis by targeting TM4SF5 and SLAMF7 linkage.

Ji Eon Kim, Hyun Su Kim, Wonsik Kim, Eun Hae Lee, Soyeon Kim, Taewoo Kim, Eun-Ae Shin, Kyung-Hee Pyo, Haesong Lee, Seo Hee Jin and 14 more

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. SLAMF7 promotes TCRαβJournal of experimental & clinical cancer research : CR · 2025
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ji Eon Kim *Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.ORCID 0000-0001-6151-2104
Hyun Su Kim *College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Pocheon-si, Gyeonggi-do, Republic of Korea.
Wonsik Kim *Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Eun Hae LeeDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Soyeon KimDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Taewoo KimCollege of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Pocheon-si, Gyeonggi-do, Republic of Korea.
Eun-Ae ShinDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Kyung-Hee PyoDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Haesong LeeDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Seo Hee JinDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Jae-Ho LeeDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Soo-Min ByeonDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Dong Joo KimDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Jinwook JeongDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Jeongwon LeeDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Minjae OhnDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Hyojung LeeDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Su Jong YuDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Dongyun ShinCollege of Pharmacy, Gachon University, Incheon, Republic of Korea.
Semi KimMicrobiome Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Jun Yeob YooCHA Advanced Research Institute, Seongnam-si, Gyeonggi-do, Republic of Korea.
Seung-Chul LeeCHA Advanced Research Institute, Seongnam-si, Gyeonggi-do, Republic of Korea.
Young-Ger SuhCollege of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Pocheon-si, Gyeonggi-do, Republic of Korea. ygsuh@cha.ac.kr.
Jung Weon LeeDepartment of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Republic of Korea. jwl@snu.ac.kr.ORCID 0000-0003-2722-8200

Funding

National Research Foundation of Korea (NRF) NRF-2020R1A2C3008993National Research Foundation of Korea (NRF) NRF-2021M3A9D3024752National Research Foundation of Korea (NRF) NRF-2022R1C1C2003502
6 · The paper itself

Abstract

Dynamic communication between hepatocytes and the environment is critical in hepatocellular carcinoma (HCC) development. Clinical immunotherapy against HCC is currently unsatisfactory and needs more systemic considerations, including the identification of new biomarkers and immune checkpoints. Transmembrane 4 L six family member 5 (TM4SF5) is known to promote HCC, but it remains unclear how cancerous hepatocytes avoid immune surveillance and whether avoidance can be blocked. We investigated how TM4SF5-mediated hepatic tumorigenesis avoids surveillance by natural killer (NK) cells, which are prevalent in the liver, and whether the avoidance can be blocked by anti-TM4SF5 agents. We used comprehensive structure activity relationship analysis to identify TM4SF5-specific isoxazole (TSI)-based small molecules that inhibit TM4SF5-mediated effects. TM4SF5 expressed by hepatocytes reduced NK cell cytotoxicity by downregulating stimulatory ligands/receptors, including signaling lymphocytic activation molecule family member 7 (SLAMF7). TM4SF5 bound SLAMF7 depending on N-glycosylation and caused intracellular trafficking of SLAMF7 from the plasma membrane to lysosomes for degradation. TSI treatments in cell lines and animal models of HCC blocked this binding, intracellular trafficking, and downregulation, resulting in higher levels of stimulatory NK cell ligands. In mouse xenograft models, TSI treatment abrogated HCC development by increasing the abundance and dispersion of Slamf7-positive cells in liver tissues, recapitulating the phenotype of Tm4sf5-knockout mice and indicating TSI-mediated restoration of NK cell surveillance. These findings suggest that TSIs can inhibit TM4SF5-mediated liver carcinogenesis by increasing NK cell surveillance.

Indexed as

Carcinoma, HepatocellularKiller Cells, NaturalLiver NeoplasmsMembrane ProteinsSignaling Lymphocytic Activation Molecule FamilyAnimalsCarcinogenesisHepatocytesHumansImmunologic SurveillanceMiceMembrane ProteinsSignaling Lymphocytic Activation Molecule FamilySLAMF7 protein, humanTM4SF5 protein, human

Identifiers

PMID39828766
PMCPMC11743776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.